Cargando…

Switching to an alternative biological agent in juvenile idiopathic arthritis (I)

Detalles Bibliográficos
Autores principales:	Remesal, A, Murias, S, Gonzalez, MI, Tarjuelo, I, Merino, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194516/ http://dx.doi.org/10.1186/1546-0096-9-S1-P162

Ejemplares similares

Switching to an alternative biological agent in juvenile idiopathic arthritis (II)
por: Murias, S, et al.
Publicado: (2011)

PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis
por: Woerner, A, et al.
Publicado: (2013)

Juvenile idiopathic arthritis treated with biological therapies
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012)

Impact of biologics on growth in children with juvenile idiopathic arthritis
por: Uettwiller, F, et al.
Publicado: (2011)

Renal disorder and biological treatment in juvenile idiopathic arthritis
por: Mateescu, Lidia, et al.
Publicado: (2014)

Switch of biotherapies in patients with juvenile idiopathic arthritis: analyses of the JIR cohort data
por: Piram, Maryam, et al.
Publicado: (2014)

Ten years of experience of biologics in juvenile idiopathic arthritis: focus for the reasons of withdrawals
por: Arsenyeva, Svetlana V, et al.
Publicado: (2014)

Prescribed but not approved: biologic agents used without approval in juvenile idiopathic arthritis in Switzerland, France and Belgium
por: Woerner, Andreas, et al.
Publicado: (2014)

Eight years of experience with biological treatment in juvenile idiopathic arthritis
por: Mourão, A F, et al.
Publicado: (2010)

An alternative analgesic agent for intra-articular corticosteroid injections (IAI) in juvenile idiopathic arthritis (JIA) – a fentanyl lollipop
por: Zareen, Z, et al.
Publicado: (2011)

Phenotypes of juvenile idiopathic arthritis
por: Rokhlina, Faina, et al.
Publicado: (2014)

Analysis of the classical, alternative, and MBL pathways of the complement system in juvenile idiopathic arthritis
por: Brunner, J, et al.
Publicado: (2008)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

MRI evaluation of clinical remission in juvenile idiopathic arthritis
por: van Veenendaal, M, et al.
Publicado: (2011)

Juvenile idiopathic arthritis: the transition to adulthood
por: Fernandes, Susana, et al.
Publicado: (2014)

A family carrying a homozygous LACC1 truncated mutation expands the clinical phenotype of this disease beyond systemic-onset juvenile idiopathic arthritis
por: Arostegui, JI, et al.
Publicado: (2015)

Multicenter retrospective study of biological tolerance in juvenile idiopathic arthritis (jir-cohort)
por: Cabrera, Natalia, et al.
Publicado: (2014)

Systemic juvenile idiopathic arthritis in the republic of Bashkortostan
por: Malievskiy, VA
Publicado: (2011)

Familial hypercholesterolemia misinterpreted as juvenile idiopathic arthritis
por: Schou, AJ, et al.
Publicado: (2011)

Clinical and articular presentation of juvenile idiopathic arthritis
por: Ravichandran, R, et al.
Publicado: (2008)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

Depression, anxiety and pain in juvenile idiopathic arthritis
por: Erdogdu, D, et al.
Publicado: (2008)

Illness representation in adolescents with juvenile idiopathic arthritis
por: Lelieveld, OTHM, et al.
Publicado: (2008)

TH17-phenotypes of juvenile idiopathic arthritis
por: Turtsevich, Inga Z, et al.
Publicado: (2014)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Juvenile idiopathic arthritis is a diagnosis of exclusion
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

PReS-FINAL-2052: Costs of biologics in juvenile idiopathic arthritis: past, present and future
por: Prince, FH, et al.
Publicado: (2013)

PReS-FINAL-2146: Trends in prescription of biologics and outcomes of juvenile idiopathic arthritis; results of the Dutch national arthritis and biologicals in children register
por: Otten, MH, et al.
Publicado: (2013)

Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries
por: Swart, Joost, et al.
Publicado: (2014)

Ankle arthritis predicts worse outcome in children with juvenile idiopathic arthritis
por: Esbjörnsson, Anna-Clara, et al.
Publicado: (2014)

Macrophage activation syndrome during treatment with biological therapy in patients with systemic juvenile idiopathic arthritis
por: Boteanu, Alina Lucica, et al.
Publicado: (2014)

Genetic markers in clinical subtypes of juvenile idiopathic arthritis
por: Le Blay, Pierre, et al.
Publicado: (2011)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Coeliac disease and intestinal inflammation in juvenil idiopathic arthritis
por: Nuñez, Esmeralda, et al.
Publicado: (2011)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Genetic susceptibility to juvenile idiopathic arthritis in Iranian children
por: Shiari, Reza, et al.
Publicado: (2011)

Early treatment with infliximab in patients with juvenile idiopathic arthritis
por: Sleptsova, TV, et al.
Publicado: (2011)

Early untreated juvenile idiopathic arthritis: predictors of outcome
por: Pascoli, L, et al.
Publicado: (2008)

Temporomandibular joint involvement in children with juvenile idiopathic arthritis
por: Cannizzaro, E, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_nja665896rdnpg9dsfipogipfu